Shares of Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) dropped 1.2% during trading on Tuesday . The company traded as low as $9.16 and last traded at $9.18, with a volume of 535,272 shares traded. The stock had previously closed at $9.29.

ACHN has been the topic of a number of analyst reports. Chardan Capital initiated coverage on Achillion Pharmaceuticals in a research report on Thursday, July 14th. They issued a “sell” rating and a $4.00 price target on the stock. Robert W. Baird reissued an “outperform” rating and issued a $10.00 price target on shares of Achillion Pharmaceuticals in a research report on Monday, June 6th. Zacks Investment Research cut Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, April 27th. Leerink Swann reissued a “hold” rating and issued a $9.00 price target on shares of Achillion Pharmaceuticals in a research report on Wednesday, May 25th. Finally, JMP Securities raised Achillion Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $13.00 price target on the stock in a research report on Thursday, July 7th. One analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $9.63.

The firm has a 50-day moving average price of $8.73 and a 200 day moving average price of $8.20. The stock has a market capitalization of $1.26 billion and a P/E ratio of 188.16.

Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.14) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.01. During the same quarter in the previous year, the business earned ($0.25) EPS. Equities research analysts anticipate that Achillion Pharmaceuticals Inc. will post ($0.63) earnings per share for the current year.

An institutional investor recently raised its position in Achillion Pharmaceuticals stock. Rhumbline Advisers increased its position in Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) by 14.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 117,525 shares of the biopharmaceutical company’s stock after buying an additional 14,425 shares during the period. Rhumbline Advisers owned 0.09% of Achillion Pharmaceuticals worth $1,268,000 at the end of the most recent reporting period.

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.